Global Information
회사소개 | 문의 | 위시리스트

겸상 적혈구증(SCD) : 역학 예측(2028년)

Sickle Cell Disease (SCD) - Epidemiology Forecast - 2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 11월 상품 코드 534989
페이지 정보 영문 60 Pages
가격
US $ 3,250 ₩ 3,831,000 PDF by E-mail (Single User License)
US $ 6,500 ₩ 7,662,000 PDF by E-mail (Site License)
US $ 9,750 ₩ 11,493,000 PDF by E-mail (Global License)


겸상 적혈구증(SCD) : 역학 예측(2028년) Sickle Cell Disease (SCD) - Epidemiology Forecast - 2028
발행일 : 2019년 11월 페이지 정보 : 영문 60 Pages

7개 신흥 시장(터키, 사우디아라비아, 아랍에미리트, 멕시코, 콜롬비아, 브라질, 아르헨티나)에서 겸상 적혈구증(SCD : Sickle Cell Disease)의 2017년 유병 수는 14만 3,306명으로 추산되고 있습니다.

7개 신흥 시장(터키, 사우디아라비아, 아랍에미리트, 멕시코, 콜롬비아, 브라질, 아르헨티나)의 겸상 적혈구증(SCD)을 조사했으며, 질병 개요 및 현행 치료법, 역학적 예측, 시장 규모, 병형·임상 증상별 유병 수의 추이와 예측, 미충족 요구 등을 정리하여 전해드립니다.

목차

제1장 시장의 개요

제2장 겸상 적혈구증(SCD)의 환자 분포

  • 환자 분포(실수치·예측)

제3장 서론

  • 질병 배경과 개요
  • 분류
  • 원인
  • 위험인자
  • 합병증
  • 증상
  • 병태생리
  • 진단

제4장 주요 조사 결과

  • 7개 신흥 시장 겸상 적혈구증(SCD)의 총유병 수
  • 7개 신흥 시장 겸상 적혈구증(SCD)의 진단 수

제5장 7개 신흥 시장 겸상 적혈구증(SCD)의 역학 : 국가별

  • 가정과 이론적 근거
  • 사우디아라비아
    • 겸상 적혈구증(SCD)의 유병 수
    • 겸상 적혈구증(SCD)의 진단 수
    • 겸상 적혈구증(SCD)의 유병 수 : 병형별
    • 겸상 적혈구증(SCD)의 유병 수 : 임상 증상별
  • 아랍에미리트(UAE)
    • 겸상 적혈구증(SCD)의 유병 수
    • 겸상 적혈구증(SCD)의 진단 수
    • 겸상 적혈구증(SCD)의 유병 수 : 병형별
    • 겸상 적혈구증(SCD)의 유병 수 : 임상 증상별
  • 터키
    • 겸상 적혈구증(SCD)의 유병 수
    • 겸상 적혈구증(SCD)의 진단 수
    • 겸상 적혈구증(SCD)의 유병 수 : 병형별
    • 겸상 적혈구증(SCD)의 유병 수 : 임상 증상별
  • 멕시코
    • 겸상 적혈구증(SCD)의 유병 수
    • 겸상 적혈구증(SCD)의 진단 수
    • 겸상 적혈구증(SCD)의 유병 수 : 병형별
    • 겸상 적혈구증(SCD)의 유병 수 : 임상 증상별
  • 브라질
    • 겸상 적혈구증(SCD)의 유병 수
    • 겸상 적혈구증(SCD)의 진단 수
    • 겸상 적혈구증(SCD)의 유병 수 : 병형별
    • 겸상 적혈구증(SCD)의 유병 수 : 임상 증상별
  • 아르헨티나
    • 겸상 적혈구증(SCD)의 유병 수
    • 겸상 적혈구증(SCD)의 진단 수
    • 겸상 적혈구증(SCD)의 유병 수 : 병형별
    • 겸상 적혈구증(SCD)의 유병 수 : 임상 증상별
  • 콜롬비아
    • 겸상 적혈구증(SCD)의 유병 수
    • 겸상 적혈구증(SCD)의 진단 수
    • 겸상 적혈구증(SCD)의 유병 수 : 병형별
    • 겸상 적혈구증(SCD)의 유병 수 : 임상 증상별

제6장 겸상 적혈구증(SCD)의 치료와 관리

  • 혈관 폐쇄 위기
  • 만성질환
  • 기타 유망 치료법

제7장 미충족 요구

제8장 부록

  • 조사 방법

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

KSA 19.11.08

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1: Laboratory test schedule for patients with SCD
  • Table 2: Total Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Table 3: Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Table 4: Total Prevalent Cases of SCD trait in Saudi Arabia (2017-2028)
  • Table 5: Total Prevalent Cases of SCD in Saudi Arabia (2017-2028)
  • Table 6: Total Diagnosed Cases of SCD in Saudi Arabia (2017-2028)
  • Table 7: Type-specific prevalence of SCD in Saudi Arabia (2017-2028)
  • Table 8: Clinical manifestations of SCD in Saudi Arabia (2017-2028)
  • Table 9: Total Prevalent Cases of SCD trait in U.A.E. (2017-2028)
  • Table 10: Total Prevalent Cases of SCD in U.A.E. (2017-2028)
  • Table 11: Total Diagnosed Cases of SCD in U.A.E. (2017-2028)
  • Table 12: Type-specific prevalence of SCD in U.A.E. (2017-2028)
  • Table 13: Clinical manifestations of SCD in U.A.E. (2017-2028)
  • Table 14: Total Prevalent Cases of SCD trait in Turkey (2017-2028)
  • Table 15: Total Prevalent Cases of SCD in Turkey (2017-2028)
  • Table 16: Total Diagnosed Cases of SCD in Turkey (2017-2028)
  • Table 17: Type-specific prevalence of SCD in Turkey (2017-2028)
  • Table 18: Clinical manifestations of SCD in Turkey (2017-2028)
  • Table 19: Total Prevalent Cases of SCD trait in Mexico (2017-2028)
  • Table 20: Total Prevalent Cases of SCD in Mexico (2017-2028)
  • Table 21: Total Diagnosed Cases of SCD in Mexico (2017-2028)
  • Table 22: Type-specific prevalence of SCD in Mexico (2017-2028)
  • Table 23: Clinical manifestations of SCD in Mexico (2017-2028)
  • Table 24: Total Prevalent Cases of SCD trait in Brazil (2017-2028)
  • Table 25: Total Prevalent Cases of SCD in Brazil (2017-2028)
  • Table 26: Total Diagnosed Cases of SCD in Brazil (2017-2028)
  • Table 27: Type-specific prevalence of SCD in Brazil (2017-2028)
  • Table 28: Clinical manifestations of SCD in Brazil (2017-2028)
  • Table 29: Total Prevalent Cases of SCD trait in Argentina (2017-2028)
  • Table 30: Total Prevalent Cases of SCD in Argentina (2017-2028)
  • Table 31: Total Diagnosed Cases of SCD in Argentina (2017-2028)
  • Table 32: Type-specific prevalence of SCD in Argentina (2017-2028)
  • Table 33: Clinical manifestations of SCD in Argentina (2017-2028)
  • Table 34: Total Prevalent Cases of SCD trait in Colombia (2017-2028)
  • Table 35: Total Prevalent Cases of SCD in Colombia (2017-2028)
  • Table 36: Total Diagnosed Cases of SCD in Colombia (2017-2028)
  • Table 37: Type-specific prevalence of SCD in Colombia (2017-2028)
  • Table 38: Clinical manifestations of SCD in Colombia (2017-2028)
  • Figure 1: Sickle Cell Disease classification
  • Figure 2: SCD complications
  • Figure 3: Common symptoms associated with Sickle Cell Disease
  • Figure 4: Induction of Red-Cell Sickling by Polymerization of Deoxy-hemoglobin-S
  • Figure 5: Principal Mechanisms Responsible for Potassium and Water Loss in Sickle Red Cells.
  • Figure 6: Principal Interactions Responsible for the Adhesion of a Sickle Red Cell to the Microvascular Endothelium
  • Figure 7: Total Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 8: Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 9: Total Prevalent Cases of SCD trait in Saudi Arabia (2017-2028)
  • Figure 10: Total Prevalent Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 11: Total Diagnosed Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 12: Type-specific prevalence of SCD in Saudi Arabia (2017-2028)
  • Figure 13: Clinical manifestations of SCD in Saudi Arabia (2017-2028)
  • Figure 14: Total Prevalent Cases of SCD trait in U.A.E. (2017-2028)
  • Figure 15: Total Prevalent Cases of SCD in U.A.E. (2017-2028)
  • Figure 16: Total Diagnosed Cases of SCD in U.A.E. (2017-2028)
  • Figure 17: Type-specific prevalence of SCD in U.A.E. (2017-2028)
  • Figure 18: Clinical manifestations of SCD in U.A.E. (2017-2028)
  • Figure 19: Total Prevalent Cases of SCD trait in Turkey (2017-2028)
  • Figure 20: Total Prevalent Cases of SCD in Turkey (2017-2028)
  • Figure 21: Total Diagnosed Cases of SCD in Turkey (2017-2028)
  • Figure 22: Type-specific prevalence of SCD in Turkey (2017-2028)
  • Figure 23: Clinical manifestations of SCD in Turkey (2017-2028)
  • Figure 24: Total Prevalent Cases of SCD trait in Mexico (2017-2028)
  • Figure 25: Total Prevalent Cases of SCD in Mexico (2017-2028)
  • Figure 26: Total Diagnosed Cases of SCD in Mexico (2017-2028)
  • Figure 27: Type-specific prevalence of SCD in Mexico (2017-2028)
  • Figure 28: Clinical manifestations of SCD in Mexico (2017-2028)
  • Figure 29: Total Prevalent Cases of SCD trait in Brazil (2017-2028)
  • Figure 30: Total Prevalent Cases of SCD in Brazil (2017-2028)
  • Figure 31: Total Diagnosed Cases of SCD in Brazil (2017-2028)
  • Figure 32: Type-specific prevalence of SCD in Brazil (2017-2028)
  • Figure 33: Clinical manifestations of SCD in Brazil (2017-2028)
  • Figure 34: Total Prevalent Cases of SCD trait in Argentina (2017-2028)
  • Figure 35: Total Prevalent Cases of SCD in Argentina (2017-2028)
  • Figure 36: Total Diagnosed Cases of SCD in Argentina (2017-2028)
  • Figure 37: Type-specific prevalence of SCD in Argentina (2017-2028)
  • Figure 38: Clinical manifestations of SCD in Argentina (2017-2028)
  • Figure 39: Total Prevalent Cases of SCD trait in Colombia (2017-2028)
  • Figure 40: Total Prevalent Cases of SCD in Colombia (2017-2028)
  • Figure 41: Total Diagnosed Cases of SCD in Colombia (2017-2028)
  • Figure 42: Type-specific prevalence of SCD in Colombia (2017-2028)
  • Figure 43: Clinical manifestations of SCD in Colombia (2017-2028)

Figure 44 Treatment algorithm for SCD

Figure 45 Measure of pain intensity and location

  • Figure 46: Schematic diagram of the mechanisms of action of pathophysiology based new therapeutic options for treatment of Sickle Cell Disease
  • Figure 47: Unmet needs for Sickle Cell Disease

List of Figures

  • Figure 1: Sickle Cell Disease classification
  • Figure 2: SCD complications
  • Figure 3: Common symptoms associated with Sickle Cell Disease
  • Figure 4: Induction of Red-Cell Sickling by Polymerization of Deoxy-hemoglobin-S
  • Figure 5: Principal Mechanisms Responsible for Potassium and Water Loss in Sickle Red Cells.
  • Figure 6: Principal Interactions Responsible for the Adhesion of a Sickle Red Cell to the Microvascular Endothelium
  • Figure 7: Total Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 8: Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 9: Total Prevalent Cases of SCD trait in Saudi Arabia (2017-2028)
  • Figure 10: Total Prevalent Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 11: Total Diagnosed Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 12: Type-specific prevalence of SCD in Saudi Arabia (2017-2028)
  • Figure 13: Clinical manifestations of SCD in Saudi Arabia (2017-2028)
  • Figure 14: Total Prevalent Cases of SCD trait in U.A.E. (2017-2028)
  • Figure 15: Total Prevalent Cases of SCD in U.A.E. (2017-2028)
  • Figure 16: Total Diagnosed Cases of SCD in U.A.E. (2017-2028)
  • Figure 17: Type-specific prevalence of SCD in U.A.E. (2017-2028)
  • Figure 18: Clinical manifestations of SCD in U.A.E. (2017-2028)
  • Figure 19: Total Prevalent Cases of SCD trait in Turkey (2017-2028)
  • Figure 20: Total Prevalent Cases of SCD in Turkey (2017-2028)
  • Figure 21: Total Diagnosed Cases of SCD in Turkey (2017-2028)
  • Figure 22: Type-specific prevalence of SCD in Turkey (2017-2028)
  • Figure 23: Clinical manifestations of SCD in Turkey (2017-2028)
  • Figure 24: Total Prevalent Cases of SCD trait in Mexico (2017-2028)
  • Figure 25: Total Prevalent Cases of SCD in Mexico (2017-2028)
  • Figure 26: Total Diagnosed Cases of SCD in Mexico (2017-2028)
  • Figure 27: Type-specific prevalence of SCD in Mexico (2017-2028)
  • Figure 28: Clinical manifestations of SCD in Mexico (2017-2028)
  • Figure 29: Total Prevalent Cases of SCD trait in Brazil (2017-2028)
  • Figure 30: Total Prevalent Cases of SCD in Brazil (2017-2028)
  • Figure 31: Total Diagnosed Cases of SCD in Brazil (2017-2028)
  • Figure 32: Type-specific prevalence of SCD in Brazil (2017-2028)
  • Figure 33: Clinical manifestations of SCD in Brazil (2017-2028)
  • Figure 34: Total Prevalent Cases of SCD trait in Argentina (2017-2028)
  • Figure 35: Total Prevalent Cases of SCD in Argentina (2017-2028)
  • Figure 36: Total Diagnosed Cases of SCD in Argentina (2017-2028)
  • Figure 37: Type-specific prevalence of SCD in Argentina (2017-2028)
  • Figure 38: Clinical manifestations of SCD in Argentina (2017-2028)
  • Figure 39: Total Prevalent Cases of SCD trait in Colombia (2017-2028)
  • Figure 40: Total Prevalent Cases of SCD in Colombia (2017-2028)
  • Figure 41: Total Diagnosed Cases of SCD in Colombia (2017-2028)
  • Figure 42: Type-specific prevalence of SCD in Colombia (2017-2028)
  • Figure 43: Clinical manifestations of SCD in Colombia (2017-2028)

Figure 44 Treatment algorithm for SCD

Figure 45 Measure of pain intensity and location

  • Figure 46: Schematic diagram of the mechanisms of action of pathophysiology based new therapeutic options for treatment of Sickle Cell Disease
  • Figure 47: Unmet needs for Sickle Cell Disease

DelveInsight's 'Sickle Cell Disease (SCD)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of SCD in the 7 Emerging Markets (EM) i.e., Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina.

Geography Covered

  • Middle East (Turkey, Saudi Arabia , UAE)
  • Latin America (Mexico, Colombia, Brazil, Argentina)

Study Period: 2017-2028

Sickle Cell Disease (SCD) - Disease Understanding

The DelveInsight Sickle Cell Disease epidemiology report gives the thorough understanding of the SCD by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Sickle Cell Disease in the 7 Emerging Markets (EM), i.e., Turkey, Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina. Sickle Cell Disease (SCD) is the name given to a group of lifelong inherited conditions that affect hemoglobin. It is characterized as a chronic hemolytic disorder that is marked by tendency of hemoglobin molecules within red blood cells to polymerize and deform the red cell into sickle (or crescent) shape (Hb S) resulting in characteristic vaso-occlusive events and accelerated hemolysis.

Sickle Cell Disease (SCD) Epidemiology

The Sickle Cell Disease (SCD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 emerging markets. The epidemiology data for Sickle Cell Disease epidemiology are studied through all possible division to give a better understanding about the Disease scenario in 7EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Sickle Cell Disease Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalence of Sickle Cell Disease in 7 EM, diagnosed prevalence of Sickle Cell Disease in 7 EM) scenario of Sickle Cell Disease(SCD) in the 7EM covering Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7EM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, Total prevalent population of Sickle Cell Disease in 7 EM was observed to be 143,306 cases in 2017.

Report Scope

  • The report covers the descriptive overview of Sickle Cell Disease , explaining its causes and currently available therapies
  • Comprehensive insight has been provided into the epidemiology of the Sickle Cell Disease and its treatment in the 7 EM.
  • A detailed review of global historical and forecasted Sickle Cell Disease epidemiology is included in the report, covering drug all 7 EM.

Sickle Cell Disease Report Key Strengths

  • 10 Years Forecast
  • 7EM Coverage
  • Epidemiology Segmentation

Sickle Cell Disease Epidemiology Segmentation

  • Total prevalence of Sickle Cell Disease in 7 EM
  • Diagnosed prevalence of Sickle Cell Disease in 7 EM
  • Type Specific prevalence of Sickle Cell Disease in 7 EM
  • Clinical Manifestations of Sickle Cell Disease in 7 EM

Table of Contents

1. Sickle Cell Disease Market Overview at a Glance

2. Patient Share (%) Distribution of Sickle Cell Disease

  • 2.1. Patinet Share (%) Distribution of Sickle Cell Disease

3. Introduction

  • 3.1. Disease Background and Overview
  • 3.2. Classification of Sickle Cell Disease
  • 3.3. Causes
  • 3.4. Associated risk factors
  • 3.5. Complications
  • 3.6. Symptoms
  • 3.7. Pathophysiology
  • 3.8. Diagnosis
  • 3.9. Seven Emerging Markets (EM) Total Prevalent Patient Population of Sickle Cell Disease (SCD)

4. Key Findings

  • 4.1. Total Prevalence of Sickle Cell Disease in 7 Emerging Markets
  • 4.2. Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets
  • 4.3. Country Wise-Epidemiology of Sickle Cell Disease (SCD)

5. Emerging Markets: Assumptions and Rationale

  • 5.1. Saudi Arabia
  • 5.2. Total Prevalent Cases of SCD trait in Saudi Arabia
    • 5.2.1. Total Prevalent Cases of SCD in Saudi Arabia
    • 5.2.2. Diagnosed Cases of SCD in Saudi Arabia
    • 5.2.3. Type-specific prevalence of SCD in Saudi Arabia
    • 5.2.4. Clinical manifestations of SCD in Saudi Arabia
    • 5.2.5. U.A.E.
  • 5.3. Total Prevalent Cases of SCD trait in U.A.E.
    • 5.3.1. Total Prevalent Cases of SCD in U.A.E.
    • 5.3.2. Diagnosed Cases of SCD in U.A.E.
    • 5.3.3. Type-specific prevalence of SCD in U.A.E.
    • 5.3.4. Clinical manifestations of SCD in U.A.E.
    • 5.3.5. Turkey
  • 5.4. Total Prevalent Cases of SCD trait in Turkey
    • 5.4.1. Total Prevalent Cases of SCD in Turkey
    • 5.4.2. Diagnosed Cases of SCD in Turkey
    • 5.4.3. Type-specific prevalence of SCD in Turkey
    • 5.4.4. Clinical manifestations of SCD in Turkey
    • 5.4.5. Mexico
  • 5.5. Total Prevalent Cases of SCD trait in Mexico
    • 5.5.1. Total Prevalent Cases of SCD in Mexico
    • 5.5.2. Diagnosed Cases of SCD in Mexico
    • 5.5.3. Type-specific prevalence of SCD in Mexico
    • 5.5.4. Clinical manifestations of SCD in Mexico
    • 5.5.5. Brazil
  • 5.6. Total Prevalent Cases of SCD trait in Brazil
    • 5.6.1. Total Prevalent Cases of SCD in Brazil
    • 5.6.2. Diagnosed Cases of SCD in Brazil
    • 5.6.3. Type-specific prevalence of SCD in Brazil
    • 5.6.4. Clinical manifestations of SCD in Brazil
    • 5.6.5. Argentina
  • 5.7. Total Prevalent Cases of SCD trait in Argentina
    • 5.7.1. Total Prevalent Cases of SCD in Argentina
    • 5.7.2. Diagnosed Cases of SCD in Argentina
    • 5.7.3. Type-specific prevalence of SCD in Argentina
    • 5.7.4. Clinical manifestations of SCD in Argentina
    • 5.7.5. Colombia
  • 5.8. Total Prevalent Cases of SCD trait in Colombia
    • 5.8.1. Total Prevalent Cases of SCD in Colombia
    • 5.8.2. Diagnosed Cases of SCD in Colombia
    • 5.8.3. Type-specific prevalence of SCD in Colombia
    • 5.8.4. Clinical manifestations of SCD in Colombia
    • 5.8.5. Treatment and Management of Sickle Cell Disease

6. Treatment and Management of Sickle Cell Disease

  • 6.1. Vaso-occlusive crisis
  • 6.2. Chronic disease
  • 6.3. Other promising therapeutic approaches

7. Unmet Needs

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Back to Top
전화 문의
F A Q